Immunogenic and Protective Properties of Neisseria meningitidis IgA1 Protease and of Its Truncated Fragments
- Autores: Zinchenko A.A.1, Kotelnikova O.V.1, Gordeeva E.A.1, Prokopenko Y.A.1, Razgulyaeva O.A.1, Serova O.V.1, Melikhova T.D.1, Nokel E.A.1, Zhigis L.S.1, Zueva V.S.1, Alliluev A.P.2, Rumsh L.D.1
-
Afiliações:
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
- Central Research Institute of Epidemiology of the Federal Service on Customers’ Rights Protection and Human Well-Being Surveillance
- Edição: Volume 44, Nº 1 (2018)
- Páginas: 64-72
- Seção: Article
- URL: https://bakhtiniada.ru/1068-1620/article/view/228819
- DOI: https://doi.org/10.1134/S1068162018010193
- ID: 228819
Citar
Resumo
Four recombinant proteins, MA28–P1004LEH6, ME135–H328LEH6, MW329–H622LEH6 and MH835–P1004LEH6, were prepared based on the genomic sequence of IgA1 protease from Neisseria meningitidis serogroup B strain H44/76. The immunogenic and protective properties of these proteins were studied in a mouse model. The predicted T- and B-epitopes located in the N-terminal part of amino acid sequence of this enzyme are very important for the formation of effective protection against meningococci of the three main epidemic serogroups A, B, and C. The small-sized recombinant protein having the sequence ME135–H328LEH6 (molecular weight 23367 Da) appears to be as protective against meningococci of the tested serogroups as the high molecular MA28–P1004LEH6 (molecular weight 109019 Da), the latter being a large-sized analog of full-length IgA1 protease. These proteins can be promising candidates for a polyvalent meningococcal vaccine.
Palavras-chave
Sobre autores
A. Zinchenko
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: zhigis@mail.ibch.ru
Rússia, Moscow, 117997
O. Kotelnikova
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: zhigis@mail.ibch.ru
Rússia, Moscow, 117997
E. Gordeeva
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: zhigis@mail.ibch.ru
Rússia, Moscow, 117997
Yu. Prokopenko
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: zhigis@mail.ibch.ru
Rússia, Moscow, 117997
O. Razgulyaeva
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: zhigis@mail.ibch.ru
Rússia, Moscow, 117997
O. Serova
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: zhigis@mail.ibch.ru
Rússia, Moscow, 117997
T. Melikhova
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: zhigis@mail.ibch.ru
Rússia, Moscow, 117997
E. Nokel
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: zhigis@mail.ibch.ru
Rússia, Moscow, 117997
L. Zhigis
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Autor responsável pela correspondência
Email: zhigis@mail.ibch.ru
Rússia, Moscow, 117997
V. Zueva
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: zhigis@mail.ibch.ru
Rússia, Moscow, 117997
A. Alliluev
Central Research Institute of Epidemiology of the Federal Service on Customers’ Rights Protection and Human Well-Being Surveillance
Email: zhigis@mail.ibch.ru
Rússia, Moscow, 111123
L. Rumsh
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: zhigis@mail.ibch.ru
Rússia, Moscow, 117997
Arquivos suplementares
